fbpx
QQQ
+ 0.89
341.75
+ 0.26%
DIA
+ 5.00
327.96
+ 1.5%
SPY
+ 5.00
409.93
+ 1.2%
TLT
-1.67
147.40
-1.15%
GLD
+ 1.96
162.97
+ 1.19%

Eledon Pharma Stock Jumps Despite FDA Asking For Additional Preclinical Study In Non-Primate Animal Models

April 27, 2021 7:55 am
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Eledon Pharma Stock Jumps Despite FDA Asking For Additional Preclinical Study In Non-Primate Animal Models
  • As part of ongoing discussions with the FDA regarding Eledon Pharmaceuticals Inc's (NASDAQ: ELDN) AT-1501 renal transplant program, the agency has requested AT-1501 specific renal transplant data in non-human primates before starting a Phase 2 trial in renal transplantation in the U.S.
  • Hence, Eledon plans to initiate an evaluation of AT-1501 in a standard non-human primate model of renal transplantation, which is expected to be completed by late 2022.
  • No significant drug-related safety signals with AT-1501 have been identified to date. This change in development strategy is not due to any specific event or data, the company said.
  • AT-1501, the company's lead candidate, is an anti-CD40L antibody with a high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential.
  • AT-1501 is a humanized IgG1 antibody engineered to potentially both improve safety and provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other anti-CD40 approaches.
  • SVB Leerink analyst Thomas Smith maintains Eledon's Outperform rating and lowers the price target from $34 to $33.
  • Price Action: ELDN shares are up 7.1% at $11.48 in the premarket trading on the last check Tuesday.

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to our YouTube channel.